Clinical Trial Designs for Predictive Biomarker Validation: One Size Does Not Fit All

REFERENCES

• Amado , R. G. , Wolf , M. , Freeman , D. , Peeters , M. , Van Cutsem , E. , Siena , S. , Suggs , S. , Devercelli , G. , Woolley , M. , Chang , D. ( 2008a ). Panitumumab (pmab) efficacy and patient-reported outcomes (PRO) in metastatic colorectal cancer (mCRC) patients (pts) with wild-type (WT) KRAS tumor status . Gastrointestinal Cancers Symposium Abstract 278 .
   Google Scholar
• Amado , R. G. , Wolf , M. , Peeters , M. , Van Cutsem , E. , Siena , S. , Freeman , D. J. , Juan , T. , Sikorski , R. , Suggs , S. , Radinsky , R. , Patterson , S. D. , Chang , D.D. ( 2008b ). Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer . J. Clin. Oncol. 26 ( 10 ): 1626 – 1634 .
   PubMed Web of Science ®Google Scholar
• Bonomi , P. D. , Buckingham , L. , Coon , J. ( 2007 ). Selecting patients for treatment with epidermal growth factor tyrosine kinase inhibitors . Clin. Cancer Res. 13 ( 15 Pt 2 ): s4606 – 4612 .
   Google Scholar
• Cappuzzo , F. , Hirsch , F. R. , Rossi , E. , Bartolini , S. , Ceresoli , G. L. , Bemis , L. , Haney , J. , Witta , S. , Danenberg , K. , Domenichini , I. , Ludovini , V. , Magrini , E. , Gregore , V. , Doglioni , C. , Sidoni , A. , Tonato , M. , Franklin , W. A. , Crino , L. , Bunn , P. A. , Jr., Varella-Garcia , M. ( 2005 ). Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer . J. Natl. Cancer Inst. 97 : 643 – 655 .
   PubMed Web of Science ®Google Scholar
• Cappuzzo , F. , Ligorio , C. , Toschi , L. , Rossi , E. , Trisolini , R. , Paioli , D. , Magrini , E. , Finocchiaro , G. , Bartolini , S. , Cancellieri , A. , Hirsch , F. R. , Crino , L. , Varella-Garcia , M. (2007). EGFR and HER2 gene copy number and response to first-line chemotherapy in patients with advanced non-small cell lung cancer (NSCLC). J. Thorac. Oncol. 2(5):423–429.
   Google Scholar
• Collett , D. ( 2003 ). Chapter 10: Sample size requirements for a survival study . In: Modeling Survival Data in Medical Research. , 2nd ed. Chapman & Hall/CRC , pp. 299 – 311 .
   Google Scholar
• Conley , B. A. , Taube , S. E. ( 2004 ). Prognostic and predictive markers in cancer . Dis. Markers 20 ( 2 ): 35 – 43 .
   Google Scholar
• Eberhard , D. A. , Johnson , B. E. , Amler , L. C. , Goddard , A. D. , Heldens , S. L. , Herbst , R. S. , Ince , W. L. , Jänne , P. A. , Januario , T. , Johnson , D. H. , Klein , P. , Miller , V. A. , Ostland , M. A. , Ramies , D. A. , Sebisanovic , D. , Stinson , J. A. , Zhang , Y. R. , Seshagiri , S. , Hillan , K. J. ( 2005 ). Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib . J. Clin. Oncol. 23 ( 25 ): 5900 – 5909 .
   PubMed Web of Science ®Google Scholar
• Freeman , D. , Juan , T. , Meropol , N. J. , Hecht , J. R. , Berlin , J. , Van Cutsem , E. , Reiner , M. , Radinsky , R. , Amado , R. G. , Peeters , M. ( 2008 ). Association of Somatic KRAS Gene Mutations and Clinical Outcome in Patients With Metastatic Colorectal Cancer Receiving Panitumumab Monotherapy . 14th European Cancer Conference, Abstract 3014 .
   Google Scholar
• Hecht , J. R. , Patnaik , A. , Berlin , J. , Venook , A. , Malik , I. , Tchekmedyian , S. , Navale , L. , Amado , R. G. , Meropol , N. J. ( 2007 ). Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer . Cancer 110 ( 5 ): 980 – 988 .
   PubMed Web of Science ®Google Scholar
• Hirsch , F. R. , Scagliotti , G. V. , Langer , C. J. , Varella-Garcia , M. , Franklin , W. A. ( 2003a ). Epidermal growth factor family of receptors in preneoplasia and lung cancer: perspectives for targeted therapies . Lung Cancer 41 ( Suppl 1 ): S29 – 42 .
   PubMedGoogle Scholar
• Hirsch , F. R. , Varella-Garcia , M. , Bunn , P. A. Jr. , Di Maria , M. V. , Veve , R. , Bremmes , R. M. , Baron , A. E. , Zeng , C. , Franklin , W. A. ( 2003b ). Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis . J. Clin. Oncol. 21 : 3798 – 3807 .
   PubMed Web of Science ®Google Scholar
• Jiang , W. , Freidlin , B. , Simon , R. ( 2007 ). Biomarker-adaptive threshold design: a procedure for evaluating treatment with possible biomarker-defined subset effect . J. Natl. Cancer Inst. 99 ( 13 ): 1036 – 1043 .
   Google Scholar
• Maitournam , A. , Simon , R. ( 2005 ). On the efficiency of targeted clinical trials . Stat. Med. 24 ( 3 ): 329 – 339 .
   PubMed Web of Science ®Google Scholar
• Mandrekar , S. J. , Grothey , A. , Goetz , M. P. , Sargent , D. J. ( 2005 ). Clinical trial designs for prospective validation of biomarkers . Am. J. Pharmacogenomics 5 ( 5 ): 317 – 325 .
   PubMedGoogle Scholar
• Paik , S. ( 2003 ). Clinical trial methods to discover and validate predictive markers for treatment response in cancer . Biotechnol. Annu. Rev. 9 : 259 – 267 .
   PubMedGoogle Scholar
• Paik , S. , Kim , C. , Jeong , J. , Geyer , C. E. , Romond , E. H. , Mejia-Mejia , O. , Mamounas , E. P. , Wickerham , D. , Costantino , J. P. , Wolmark , N. ( 2007 ). Benefit from adjuvant trastuzumab may not be confined to patients with IHC 3+ and/or FISH-positive tumors: Central testing results from NSABP B-31. ASCO Annual Meeting Proceedings Part I . J. Clin. Oncol. 25 ( 18S ): 511 .
   Google Scholar
• Pauletti , G. , Dandekar , S. , Rong , H. , Ramos , L. , Peng , H. , Seshadri , R. , Slamon , D. J. ( 2000 ). Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry . J. Clin. Oncol. 18 ( 21 ): 3651 – 3664 .
   PubMed Web of Science ®Google Scholar
• Pegram , M. D. , Konecny , G. E. , O'Callaghan , C. , Beryt , M. , Pietras , R. , Slamon , D. J. (2004). Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. J. Natl. Cancer Inst. 96(10):739–749.
   PubMed Web of Science ®Google Scholar
• Perez , E. A. , Suman , V. J. , Davidson , N. E. , Martino , S. , Kaufman , P. A. , Lingle , W. L. , Flynn , P. J. , Ingle , J. N. , Visscher , D. , Jenkins , R. B. ( 2006 ). HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial . J. Clin. Oncol. 24 ( 19 ): 3032 – 3038 .
   PubMed Web of Science ®Google Scholar
• Perez , E. A. , Romond , E. H. , Suman , V. J. , Jeong , J. , Davidson , N. E. , Geyer , C. E. , Martino , M. , Mamounas , E. P. , Kauffman , P. A. , Wolmark , N. ( 2007 ). Updated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with/without trastuzumab in patients with HER2-positive breast cancer. ASCO Annual Meeting Proceedings Part I . J. Clin. Oncol. 25 ( 18S ): 512 .
   Google Scholar
• Pietras , R. J. , Pegram , M. D. , Finn , R. S. , Maneval , D. A. , Slamon , D. J. ( 1998 ). Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs . Oncogene 17 ( 17 ): 2235 – 2249 .
   PubMed Web of Science ®Google Scholar
• Romond , E. H. , Perez , E. A. , Bryant , J. , Suman , V. J. , Geyer , C. E. Jr. , Davidson , N. E. , Tan-Chiu , E. , Martino , S. , Paik , S. , Kaufman , P. A. , Swain , S. M. , Pisansky , T. M. , Fehrenbacher , L. , Kutteh , L. A. , Vogel , V. G. , Visscher , D. W. , Yothers , G. , Jenkins , R. B. , Brown , A. M. , Dakhil , S. R. , Mamounas , E. P. , Lingle , W. L. , Klein , P. M. , Ingle , J. N. , Wolmark , N. ( 2005 ). Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer . N. Engl. J. Med. 353 ( 16 ): 1673 – 1684 .
   PubMed Web of Science ®Google Scholar
• Sargent , D. , Allegra , C. ( 2002 ). Issues in clinical trial design for tumor marker studies . Semin. Oncol. 29 ( 3 ): 222 – 230 .
   PubMed Web of Science ®Google Scholar
• Sargent , D. J. , Conley , B. A. , Allegra , C. , Collette , L. ( 2005 ). Clinical trial designs for predictive marker validation in cancer treatment trials . J. Clin. Oncol. 23 ( 9 ): 2020 – 2027 .
   PubMed Web of Science ®Google Scholar
• Sequist , L. V. , Bell , D. W. , Lynch , T. J. , Haber , D. A. ( 2007 ). Molecular predictors of response to epidermal growth factor receptor antagonists in non–small-cell lung cancer . J. Clin. Oncol. 25 ( 5 ): 587 – 595 .
   PubMed Web of Science ®Google Scholar
• Shepard , H. M. , Lewis , G. D. , Sarup , J. C. , Fendly , B. M. , Maneval , D. , Mordenti , J. , Figari , I. , Kotts , C. E. , Palladino , M. A. Jr. , et al. . ( 1991 ). Monoclonal antibody therapy of human cancer: Taking the HER2 protooncogene to the clinic . J. Clin. Immunol. 11 ( 3 ): 117 – 127 .
   PubMed Web of Science ®Google Scholar
• Shepherd , F. A. , Pereira , J. R. , et al. . ( 2005 ). Erlotinib in previously treated non–small-cell lung cancer . N. Engl. J. Med. 353 : 123 – 132 .
   PubMed Web of Science ®Google Scholar
• Simon , R. , Maitournam , A. ( 2004 ). Evaluating the efficiency of targeted designs for randomized clinical trials . Clin. Cancer Res. 10 ( 20 ): 6759 – 6763 .
   PubMed Web of Science ®Google Scholar
• Slamon , D. ( 2000 ). Herceptin: increasing survival in metastatic breast cancer . Eur. J. Oncol. Nurs. 4 ( Sa ): 24 – 29 .
   Google Scholar
• Taube , S. E. , Jacobson , J. W. , Lively , T. G. ( 2005 ). Cancer diagnostics: decision criteria for marker utilization in the clinic . Am. J. Pharmacogenomics 5 ( 6 ): 357 – 364 .
   Google Scholar
• Van Cutsem , E. , Peeters , M. , Siena , S. , Humblet , Y. , Hendlisz , A. , Neyns , B. , Canon , J. L. , Van Laethem , J. L. , Maurel , J. , Richardson , G. , Wolf , M. , Amado , R. G. ( 2007 ). Open-label Phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer . J. Clin. Oncol. 25 ( 13 ): 1658 – 1664 .
   PubMed Web of Science ®Google Scholar